Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Interest & Investment Income (2020 - 2025)

Historic Interest & Investment Income for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $2.0 million.

  • TScan Therapeutics' Interest & Investment Income fell 4473.33% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year decrease of 1576.91%. This contributed to the annual value of $12.1 million for FY2024, which is 5083.14% up from last year.
  • Latest data reveals that TScan Therapeutics reported Interest & Investment Income of $2.0 million as of Q3 2025, which was down 4473.33% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' Interest & Investment Income registered a high of $3.7 million during Q3 2024, and its lowest value of $2000.0 during Q4 2021.
  • Its 5-year average for Interest & Investment Income is $1.5 million, with a median of $1.5 million in 2023.
  • Per our database at Business Quant, TScan Therapeutics' Interest & Investment Income soared by 4495000.0% in 2022 and then crashed by 4473.33% in 2025.
  • Over the past 5 years, TScan Therapeutics' Interest & Investment Income (Quarter) stood at $2000.0 in 2021, then soared by 44950.0% to $901000.0 in 2022, then surged by 188.12% to $2.6 million in 2023, then grew by 6.97% to $2.8 million in 2024, then dropped by 26.5% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.4 million for Q2 2025, and $2.8 million during Q1 2025.